Centers for medicare & medicaid services designate the first ten pharmaceuticals for negotiation under the medicare drug price negotiation program

Abstract

The Centers for Medicare & Medicaid Services has made the initial designation of 10 pharmaceuticals for negotiation under the Medicare Drug Price Negotiation Program, and the Industry has fired the first salvo of legal challenges to the constitutionality of the Program. This article provides an initial high level review of the Program and Industry challenges, which are not expected to be resolved until the cases work their way before the U.S. Supreme Court.